Polypharmacy is the simultaneous use of two or more drugs to treat a single health condition. Polypharmacy is often used in the treatment of schizophrenia where people are regularly prescribed two or more antipsychotics, as well as antidepressants and/or benzodiazepines, although there is little evidence to prove that these combinations are more effective than monotherapy. [read the full story…]
Weight gain is one of the side effects that people who take antipsychotic drugs complain of the most. Obesity is common in this population and this can often lead to cardiovascular problems and a far shorter life expectancy than the rest of the population. As a result, there is a great deal of interest in [read the full story…]
We know that people with schizophrenia who adhere to their treatment are more likely to experience sustained periods of time without psychotic symptoms. However, lots of patients find it hard to stick to the prescribed medication, so doctors sometimes recommend alternative treatments to try and encourage adherence. Long-acting intramuscular injections are one option available to [read the full story…]
The newer second-generation antipsychotic drugs (Risperidone, Quetiapine, Amisulpride, Aripiprazole, Clozapine, Olanzapine) are promoted because they have a lower risk of extrapyramidal side effects than older drugs. Drug companies often promote these newer drugs as virtually free from extrapyramidal side effects, but the patients who take them and the clinicians who prescribe them often don’t agree. [read the full story…]
Preterm babies are three times more likely to be admitted to hospital for a mental health problem as an adult than normal term babies, according to a study published in the Archives of General Psychiatry by researchers in the UK and Sweden. About 1 in every 13 children born in the UK are classified as [read the full story…]
NICE guidance recommends offering CBT (cognitive behavioural therapy), family therapy and arts therapies for people with schizophrenia: Offer CBT to all people with schizophrenia. This can be started either during the acute phase or later, including in inpatient settings. – Taken from 1.3.4.1 in Schizophrenia (CG82). NICE, March 2009. However, CBT is still not widely [read the full story…]
There is an enormous body of research concerned with schizophrenia and the use of antipsychotic drugs. A quick search on PubMed for ‘schizophrenia, antipsychotics and randomised controlled trials’ brings back nearly 2,000 articles! The authors of a new systematic review and meta analysis published today in the Lancet, suggest that one area that has not [read the full story…]
Antipsychotic drugs are currently prescribed to a significant proportion of young people who are diagnosed with psychosis. Past research has estimated that up to half of people at risk of developing psychosis at a young age will progress to a full blown psychotic illness such as schizophrenia. A new landmark randomised controlled trial has been [read the full story…]
This is one in a series of 5 systematic reviews commissioned by the Department of Health, which seek to establish a comprehensive understanding of the distribution and pattern of psychotic disorders in England, between 1950 and 2009. All mental health professionals, commissioners and health planners will find this research relevant to their work. It’s well [read the full story…]
People with chronic mental illnesses such as schizophrenia often struggle to cope with the basic tasks that life throws at them. Their health condition and the often debilitating effects of medication can make simple things like going to the shop or cleaning the house almost insurmountable hurdles. Various rehabilitation therapies are used to help people [read the full story…]
